Loading viewer...
investor_presentation
Format: PDF investor_presentation
Inhibrx is a clinical-stage biopharmaceutical company focused on discovering and developing effective biologic treatments for life-threatening conditions using proprietary protein engineering. The company, founded in 2010 and publicly listed in 2020, has 165+ employees and maintains a differentiated pipeline of next-generation therapeutics across focused disease areas.
investor_presentation
1 Pages
Honeywell 2016 Q3 Update and FY2017 Earnings Guidance
investor_presentationinvestor_presentation
22 Pages
Honeywell International Inc.